跳到正文
专业监测临床试验状态

临床试验状态

查看登记总量、状态变化与来源证据。

查看全球线索 ↓

全球总体情况

ClinicalTrials.gov(美国登记平台)· 药物及生物制品干预性试验

不代表全球所有登记平台的全部试验

全球范围

全球登记总数

223,846

较昨日:暂无可比快照

统计日期:2026-11-10(北京时间)

采集时间:2026/11/10 05:16:18

今日统计尚未更新,显示最近一次成功快照。

重点关注 · 试验状态 (净变化与昨日快照比较)

暂停

706

较昨日:暂无快照

今日发现线索:0 条

提前终止

20,280

较昨日:暂无快照

今日发现线索:0 条

撤回

8,136

较昨日:暂无快照

今日发现线索:0 条
其他状态 (净变化与昨日快照比较)

在研 / 筹备

39,503

较昨日:暂无快照

已完成

127,076

较昨日:暂无快照

状态未知

28,145

较昨日:暂无快照

其他

0

较昨日:暂无快照

统计口径与采集状态 · 线索最近采集:2026/11/10 13:17:28

每项试验按登记号计一次,不代表全球所有登记平台的全部试验。净变化是两次快照的总量之差;今日线索按系统发现日期统计,包含历史回溯,不受下方筛选影响,列表还可能包含暂停后恢复。

ClinicalTrials.gov 最近成功采集:2026/11/10 13:17:28。

逐项基线:2026/11/3 09:25:29 建立,共 223,520 项;此前变化不保证完整。

筛选监测范围

按试验地点、发现时间和状态查询

全球 · 新增异常及后续变化

按发现时间统计,含历史回溯;不等于上方快照期间的新增事件。

导出当前异常 CSV
今日 0 条 · 昨日 2 条

匹配 33 条线索(提前终止 33 条),不代表全部新增事件。

试验提前终止状态未知 → 提前终止

High-Dose Ambroxol in GBA1-Related Parkinson

NCT06193421 · 申办者:Agyany Pharma LTD试验地点:Israel

登记停止说明(原文):Sponsor's decision

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-09发现时间:2026/11/10 01:15:50推送接口已接受
试验提前终止尚未招募 → 提前终止

A Repeat Dose Study of the Dexmedetomidine Transdermal System in Healthy Subjects

NCT07818330 · 申办者:Teikoku Pharma USA, Inc.试验地点:澳大利亚

登记停止说明(原文):Sponsor decision, after observation of adverse events

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-09发现时间:2026/11/10 01:15:50推送接口已接受
试验提前终止状态未知 → 提前终止

Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis

NCT04008316 · 申办者:Assistance Publique - Hôpitaux de Paris试验地点:法国

登记停止说明(原文):Sponser decision

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-06发现时间:2026/11/7 01:17:52推送接口已接受
试验提前终止进行中(不再招募) → 提前终止

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

NCT06006143 · 申办者:Yale University试验地点:美国

登记停止说明(原文):recruitment challenges

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-06发现时间:2026/11/7 01:17:52推送接口已接受
试验提前终止进行中(不再招募) → 提前终止

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075 · 申办者:Novartis Pharmaceuticals
试验地点:美国、Argentina、澳大利亚等 25 个国家或地区

美国、Argentina、澳大利亚、加拿大、中国、Finland、Greece、Hong Kong、Hungary、Iceland、印度、意大利、Jordan、黎巴嫩、Malaysia、Mexico、Portugal、Romania、Slovenia、South Korea、西班牙、Taiwan、Thailand、Turkey (Türkiye)、Vietnam

登记停止说明(原文):Business reasons and not based on any safety concerns.

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-06发现时间:2026/11/7 01:17:52推送接口已接受
试验提前终止招募中 → 提前终止

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05723107 · 申办者:NYU Langone Health试验地点:美国

登记停止说明(原文):Halted prematurely

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-06发现时间:2026/11/7 01:17:52推送接口已接受
试验提前终止暂停 → 提前终止

Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine

NCT04981860 · 申办者:University of Miami试验地点:美国

登记停止说明(原文):The study was terminated early due to operational feasibility challenges, including multi-site coordination and administrative barriers. The study team determined continuation was not feasible, and all study activities were discontinued.

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-05发现时间:2026/11/6 01:16:30推送接口已接受
试验提前终止状态未知 → 提前终止

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

NCT04648202 · 申办者:invoX Pharma Limited试验地点:美国、西班牙

登记停止说明(原文):The study was terminated early due to a strategic business decision by the Sponsor, unrelated to safety.

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-05发现时间:2026/11/6 01:16:30推送接口已接受
试验提前终止招募中 → 提前终止

CT-95 in Advanced Cancers Associated With Mesothelin Expression

NCT06756035 · 申办者:Context Therapeutics Inc.试验地点:美国

登记停止说明(原文):The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-05发现时间:2026/11/6 01:16:30推送接口已接受
试验提前终止招募中 → 提前终止

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

NCT05603104 · 申办者:Dr. Inge Winter试验地点:Israel

登记停止说明(原文):The site in Israel stopped recruitment due to logistic reasons. Other sites are recruiting for 2023-506602-39-00, 2023-506605-19-00, 2023-506617-21-00.

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-05发现时间:2026/11/6 01:16:30推送接口已接受
试验提前终止暂停 → 提前终止

Evaluation of Topical Application of BMX-010 in Subjects With Rosacea

NCT03756389 · 申办者:BioMimetix JV, LLC试验地点:美国

登记停止说明(原文):Re-formulation of study product needed.

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-05发现时间:2026/11/6 01:16:30推送接口已接受
试验提前终止招募中 → 提前终止

Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus

NCT06601101 · 申办者:University of Campinas, Brazil试验地点:巴西

登记停止说明(原文):Enrollment closed before the planned 36 eyes were reached because of the limited number of eligible patients and the long recruitment period (July 2024 to December 2025); 20 eyes of 19 participants were enrolled.

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-05发现时间:2026/11/6 01:16:30推送接口已接受
试验提前终止状态未知 → 提前终止

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

NCT05539157 · 申办者:Immorna Biotherapeutics, Inc.试验地点:美国

登记停止说明(原文):Due to extremely low accrual rate

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-05发现时间:2026/11/6 01:16:30推送接口已接受
试验提前终止状态未知 → 提前终止

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

NCT06041620 · 申办者:Institute of Hematology & Blood Diseases Hospital, China试验地点:中国

登记停止说明(原文):Suboptimal treatment response

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-04发现时间:2026/11/5 01:16:11未推送 / 未启用
试验提前终止进行中(不再招募) → 提前终止

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

NCT02530034 · 申办者:M.D. Anderson Cancer Center试验地点:美国

登记停止说明(原文):FDA Clinical Hold

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-04发现时间:2026/11/5 01:16:11未推送 / 未启用
试验提前终止状态未知 → 提前终止

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

NCT02669030 · 申办者:Institute for Advanced Medical Research, Alpharetta, GA试验地点:美国

登记停止说明(原文):inability to recruit volunteers

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-04发现时间:2026/11/5 01:16:11未推送 / 未启用
试验提前终止进行中(不再招募) → 提前终止

Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease

NCT04094298 · 申办者:Northwell Health试验地点:美国

登记停止说明(原文):The primary reasons for early study termination are administrative and funding issues and inability to obtain the investigational product; this lead to insufficient participant enrollment.

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-04发现时间:2026/11/5 01:16:11未推送 / 未启用
试验提前终止状态未知 → 提前终止

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

NCT06212154 · 申办者:Institute of Hematology & Blood Diseases Hospital, China试验地点:中国

登记停止说明(原文):Suboptimal treatment response

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-04发现时间:2026/11/5 01:16:11未推送 / 未启用
试验提前终止招募中 → 提前终止

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

NCT05065957 · 申办者:InnoPharmax Inc.试验地点:Taiwan

登记停止说明(原文):Dose-finding stage has been completed, and dose-expanding stage was not conducted due to design amendment.

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-04发现时间:2026/11/5 01:16:11未推送 / 未启用
试验提前终止招募中 → 提前终止

Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia

NCT06695741 · 申办者:Institute of Hematology & Blood Diseases Hospital, China试验地点:中国

登记停止说明(原文):No significant improvement in efficacy was observed.

来源:ClinicalTrials.gov(美国登记平台)来源更新:2026-11-04发现时间:2026/11/5 01:16:11未推送 / 未启用
第 1 页下一页

试验暂停不等于 FDA Clinical Hold。英文内容保留官方原文。